Monica Mazzarino, Maria Cristina Braganò, Francesco Donati, Francesco Botrè

The effect of the oral administration of propyphenazone on the urinary concentration of testosterone and 19-nortestosterone metabolites

Laboratorio Antidoping, Federazione Medico-Sportiva Italiana, Roma, Italy

INTRODUCTION

Propyphenazone belongs structurally to the group of pyrazolone derivatives and therapeutically to non-steroidal anti-inflammatory drugs (NSAID); it has also analgesic effects. It is generically used for the treatment of fever, pain during flu or cold and after vaccination [1-2]. The drug is not prescribed often nowadays because of the many significant side effects; the normal dose is 150-300 mg 1 to 3 times per day. Some athletes use pharmaceutical formulations containing propyphenazone during multi-days events to suppress pain.

This study originates from the observation of some unknown peaks detected in a considerable number of samples by the screening procedure for the anabolic steroids. The spectrum of these peaks corresponded to the propyphenazone metabolites (Figure 1). The same samples showed an unusually altered steroid profile (Table 1)

<table>
<thead>
<tr>
<th>Substance</th>
<th>Sample 1 (ng/mL)</th>
<th>Sample 2 (ng/mL)</th>
<th>Sample 3 (ng/mL)</th>
<th>Normal range(ng/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Testosterone</td>
<td>168.2</td>
<td>21.8</td>
<td>45.5</td>
<td>20-150</td>
</tr>
<tr>
<td>Epitestosterone</td>
<td>111.6</td>
<td>17.6</td>
<td>24.1</td>
<td>20-150</td>
</tr>
<tr>
<td>Androsterone</td>
<td>152.7</td>
<td>162.3</td>
<td>15.8</td>
<td>900-3000</td>
</tr>
<tr>
<td>Etiocholanolone</td>
<td>317.2</td>
<td>124.7</td>
<td>431</td>
<td>900-3000</td>
</tr>
<tr>
<td>11β-OH-androsterone</td>
<td>2.8</td>
<td>12.2</td>
<td>2.3</td>
<td>50-300</td>
</tr>
<tr>
<td>11β-OH-etiocholanolone</td>
<td>6.2</td>
<td>7.7</td>
<td>2.4</td>
<td>50-300</td>
</tr>
<tr>
<td>3α-androstan-3α,17β-diol</td>
<td>47.4</td>
<td>15.2</td>
<td>8.5</td>
<td>30-200</td>
</tr>
<tr>
<td>5β-androstan-3α,17β-diol</td>
<td>212.4</td>
<td>73.7</td>
<td>109.2</td>
<td>30-200</td>
</tr>
</tbody>
</table>

Figure 1. Total ion chromatogram of the GC-MS screening for the steroid total fraction (TMS-derivatives) (above) and spectrum and molecular formula of peaks 1 and 2 (below), corresponding respectively to the molecular structures of the propyphenazone metabolites N-demethylhydroxypropyphenazone and hydroxypropyphenazone.

This observation prompted us to study the effect of the oral administration of propyphenazone on the excretion/metabolism of testosterone and its synthetic analogues (e.g. 19-norsteroids). A single dose (a tablet containing 400 mg of propyphenazone) was taken orally by 10 healthy male volunteers, alone or concurrently with 19-norsteroids administration. Urine samples were collected every two hours, before and after drug administration.

EXPERIMENTAL SECTION

Propyphenazone excretion

The experiments have been carried out on male subjects (age 35±5 years), engaged in normal physical activity, undergoing treatment with propyphenazone. Circadian variability of the endogenous androgens profile was assessed before and after treatment with a single dose of 400 mg of propyphenazone, by collecting urine samples for three days every two hours.
The following endogenous hormones (glucuronate plus free fraction) were considered: androsterone, etiocholanolone, 11β-OH-androsterone, 11β-OH-etiocholanolone, 5α-androstane-3α,17β-diol and 5β-androstane-3α,17β-diol. The urine samples were stored on ice packs after collection to prevent changes in the concentrations of steroids caused by bacterial contamination or thermal degradation [3-5]. All concentration values were corrected for a value of the specific gravity of 1.020 g/L.

**Concurrent administration of propyphenazone, norandrostenediol and norandrostenedione**

The experiments have been carried out on five male subjects (age 35±5 years), engaged in normal physical activity, administered with 400 mg of propyphenazone, 2 mg of 19-norandrostenedione and 2 mg of 19-norandrostenediol. The norandrosterone and noretiocholanolone urinary profile was assessed before and after treatment with a single dose of 400 mg of propyphenazone, by collecting urine samples for three days every two hours (from the first urine in the morning to the last urine in the night). The urine samples were stored as described above.

**Analytical procedure**

To 3 mL of urine, 50 µL of internal standard (17α-methyltestosterone), 1 mL of phosphate buffer pH=7.4. and 30 µL of beta-glucuronidase from E. coli were added and hydrolysis was performed for 1 h at 50 °C. The buffered solution was then alkalinized with 1 mL of carbonate buffer and the steroids were extracted with 10 mL of tert-butylmethyl ether on a mechanical shaker for 5 minutes. After centrifugation, the ethereal layer was transferred and evaporated to dryness under vacuum; the residue was derivatized by 50 µL of N-methyl-N-trimethylsilyl trifluoroacetamide (MSTFA):NH₄I:Dithioerythryitol (1000:2:4 v/w/w) and 1 µL of the derivatized extract was injected directly into the injection port.

The gaschromatograph-mass spectrometer (GC-MS) system used was a Hewlett Packard 6890N GC and 5973N MSD (Agilent technologies SpA, Cernusco sul Naviglio, MI, Italy) equipped with a 17 m × 0.2 mm (i.d.), 0.11 µm film fused silica capillary column HP1 (cross linked methylsilicone). The oven temperature was set at 180 °C for 4.5 min, then programmed from 180 °C to 230 °C at 3 °C/min and then programmed from 230 °C to 290 °C at 20 °C/min and held at 290 °C for 2 min finally from 290 °C to 320 °C at 30 °C/min and held at 320 °C for 0.80 min; the temperature of the injection port and the detector was set at 280 °C, split (1:10) injection, the mass selective detector was operated in the electron impact...
(EI) mode at 70 eV. Acquisition was carried out in selected ion monitoring (SIM) of the following fragments: m/z 405 and m/z 420 for norandrosterone and noretiocholanolone, m/z 432 and m/z 417 for testosterone and epitestosterone, m/z 434 for androsterone and etiocholanolone, m/z 241 for 5α-androstane-3α,17β-diol and 5β-androstane-3α,17β-diol, m/z 522 for 11β-OH-androsterone and 11β-OH-etiocholanolone, m/z 318, 303, 361, 376 for propyphenazone metabolites. Helium gas with a flow rate of 0.8 mL/min was used.

All the values of urine concentration were calculated by the peak area of the detected signal relative to the internal standard methyltestosterone (m/z 301). Samples with pH > 7 were not included in the study. For calibration of the GC/MS instrument, the following reference mixture was used:

<table>
<thead>
<tr>
<th>Reference substance</th>
<th>Working solution (µg/mL)</th>
<th>Concentration in urine (ng/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Testosterone</td>
<td>4</td>
<td>40</td>
</tr>
<tr>
<td>Epitestosterone</td>
<td>4</td>
<td>40</td>
</tr>
<tr>
<td>Androsterone</td>
<td>200</td>
<td>2000</td>
</tr>
<tr>
<td>Etiocholanolone</td>
<td>200</td>
<td>2000</td>
</tr>
<tr>
<td>11β-hydroxyandrosterone</td>
<td>75</td>
<td>750</td>
</tr>
<tr>
<td>11β-hydroxyetiocholanolone</td>
<td>75</td>
<td>750</td>
</tr>
<tr>
<td>5α-androstane-3α,17β-diol</td>
<td>22.5</td>
<td>225</td>
</tr>
<tr>
<td>5β-androstane-3α,17β-diol</td>
<td>22.5</td>
<td>225</td>
</tr>
</tbody>
</table>

**RESULTS AND DISCUSSION**

**TREATMENT WITH PROPYPHENAZONE**

**Baseline study**

In the preliminary circadian study, single concentration data for all hormones in each urine collection (every two hours starting from 8:30 am) of each volunteer were compared with the corresponding concentration value of each hormone in the urine sample collected at 8:30 am.

The variability of the urinary concentration values of the urine samples collected from the same volunteer at the same time was very low: on the contrary, the absolute concentration values of each steroids showed marked interindividual differences. Nonetheless, the circadian trend was qualitatively the same for all volunteers: the excretion of the endogenous hormones did not show any significant variation along the day especially for testosterone and epitestosterone. (Figure 2).
**Figure 2.** Circadian variability of the urinary concentration of $\Delta=11\beta$-OH-androsterone, $\Delta=11\beta$-OH-etiocholanolone (above left); $\square$=epitestosterone, $\blacksquare$=testosterone (above right); $\bullet$=androsterone, $\bigcirc$=etiocholanolone (below left); $\bullet=5\alpha$-androstane-3$\alpha$,17$\beta$-diol, $\square=5\alpha$-androstane-3$\alpha$,17$\beta$-diol (below right).

**In-treatment profile**

Figure 3 shows the mean urinary concentration values of androgens after oral administration of propyphenazone. As it can be seen, a statistically significant variation of the urinary concentration of $11\beta$-OH-androsterone, $11\beta$-OH-etiocholanolone, androsterone and etiocholanolone, as well as of the androsterone/etiocholanolone ratio, was detected after two hours from propyphenazone administration. On the contrary, testosterone, epitestosterone, $5\alpha$-androstane-3$\alpha$,17$\beta$-diol and $5\beta$-androstane-3$\alpha$,17$\beta$-diol did not show any significant variation from the baseline profile.

**Post-treatment profile**

The follow up studies were carried out to verify whether the effect of propyphenazone was maintained even after the suspension of the administration. A reduced urinary
concentration of 11β-OH-androsterone, 11β-OH-etiocholanolone, androsterone and etiocholanolone was indeed recorded for one day; this effect was recorded in all subjects (Figure 4). The same qualitative trend was recorded for the androsterone/etiocholanolone concentration ratio (Fig. 5).

**Figure 3.** Effect of the administration of propyphenazone on the circadian variability of the urinary concentration of △=11β-OH-androsterone, ▲=11β-OH-etiocholanolone (above left); □=epitestosterone, ■=testosterone (above right); ●=androsterone, ○=etiocholanolone (below left); ●=5β-androstane-3α,17β-diol, □=5α-androstane-3α,17β-diol (below right).

**Concurrent administration of norandrostenedione/norandrostenediol and propyphenazone**

**Urinary concentration of 19-norandrosterone and 19-noretiocholanolone**

Figures 6 and 7 show the mean excretion values of both 19-norandrosterone and 19-noretiocholanolone before and after propyphenazone administration. The 19-norsteroids
excretion study indicated that, after two hours from propyphenazone administration, there was a statistical significant decrease of the measured urinary concentration of both 19-norandrosterone and 19-noretiocholanolone from baseline profile.

**Figure 4.** Circadian variability of the urinary concentration of androsterone (left A), etiocholanolone (right A), 11β-OH-androsterone (left B) and 11β-OH-etiocholanolone (right B), recorded before (open bar) and after 1 (dashed), 2 (grey), and 3 (black) days from the suspension of the treatment with propyphenazone.

**Figure 5.** Circadian variability of the urinary androsterone/etiocholanolone ratio recorded before (open bar), and after (dashed: day 1; gray: day 2) administration of propyphenazone.
Figure 6. Excretion study of 19-norandrosterone before (■) and after (□) propyphenazone administration.

Figure 7. Excretion study of 19-noretiocholanolone before (■) and after (□) propyphenazone administration.

Urinary concentration of propyphenazone metabolites

Figure 8 shows the urinary excretion profile of propyphenazone metabolites with and without 19-norsteroids administration.
CONCLUSIONS

• Propyphenazone administration caused in all volunteers a transient, but statistically significant, suppression of the absolute urinary concentration of 11β-OH-androsterone, 11β-OH-etiocholanolone, androsterone, etiocholanolone, 19-norandrosterone and 19-noretiocholanolone. No effect on the T/E ratio was recorded.
• The maximum value of the urinary concentration of the propyphenazone metabolites overlaps, in all subjects studied, with the suppression of 11β-OH-androsterone, 11β-OH-etiocholanolone, androsterone, etiocholanolone, 19-norandrosterone and 19-noretiocholanolone.
• The excretion of testosterone metabolites returns within the normal range of urinary concentration values after elimination of propyphenazone metabolites.
• The excretion of both 19-norandrosterone and 19-noretiocholanolone has a second maximum corresponding with the elimination of propyphenazone metabolites.
• Additional data are necessary to further clarify the mechanism leading to the observed effects, especially at higher doses, and also to consider other similar drugs.
• Our suggestion is to monitor propyphenazone, in all cases where an abnormal steroid profile or the presence of 19-nortestosterone metabolites is detected.

Figure 8 Urinary excretion profile of the two propyphenazone metabolites (■: N-demethylhydroxypropyphenazone; and □: hydroxypropyphenazone) with (left) and without (right) the concurrent administration of 19-norandrostenedione and 19-norandrostenediol.
ACKNOWLEDGEMENT

This work has been supported in part by a Research Grant of the Italian Department of Health (“Ministero della Salute, Commissione per la vigilanza sul doping e sulla tutela sanitaria delle attività sportive”). The Authors also wish to thank Alessandro Cianciulli for the technical support.

REFERENCES

2. Brogden RN, Drugs; 1986; 32 (Suppl 4):60-70